Cargando…
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
BACKGROUND: Newer classes of targeted drugs for moderate to severe plaque psoriasis are more effective and more expensive than older classes, posing a difficult and potentially costly decision about whether to use them as initial targeted treatments. OBJECTIVE: To estimate the clinical and economic...
Autores principales: | Hendrix, Nathaniel, Ollendorf, Daniel A., Chapman, Richard H., Loos, Anne, Liu, Shanshan, Kumar, Varun, Linder, Jeffrey A., Pearson, Steven D., Veenstra, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398188/ https://www.ncbi.nlm.nih.gov/pubmed/30479197 http://dx.doi.org/10.18553/jmcp.2018.24.12.1210 |
Ejemplares similares
-
Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008) -
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020) -
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021) -
Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018) -
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)